Singapore Paincare’s Audited FY2026 Results: Stronger Cash Flow, but No Shareholder Dividend

Singapore Paincare Holdings (SGX: FRQ) generated S$4.38 million of operating cash in the year ended 30 June 2026, up from S$2.34 million a year earlier. Yet the board proposed no FY2026 dividend, citing financial performance and working capital and capital needs. That makes the gap between cash generated by the clinics and cash available for shareholders the key question in its audited results, released on 8 October 2026. [S2, p. 87] [S3, p. 29] [S3, p. 30]

A small group profit, but a shareholder loss

Revenue rose to S$27.38 million from S$25.97 million in FY2025. Audited group profit after tax was just S$15,000, revised down from the S$42,000 reported in August’s unaudited results. The audit also changed a S$14,000 loss before tax into a S$165,000 loss before tax; a higher tax credit partly offset that change. [S2, p. 84] [S1, p. 1]

The group profit is easy to mistake for a return to earnings for shareholders. After allocating profit to minority owners of subsidiaries, the audited loss attributable to Singapore Paincare’s shareholders was S$857,000, almost unchanged from the unaudited S$858,000 loss. The FY2025 shareholder loss was S$4.03 million, so the result improved substantially, but it remained a loss. [S2, p. 84] [S3, p. 4]

The annual report attributes part of the improvement to lower goodwill impairment and a S$318,000 share of profit from a joint venture, compared with a S$733,000 share of loss in FY2025. Management says the joint venture’s swing mainly reflected a fair-value gain on its PuXiang investment. That valuation movement should not be read as recurring cash from Singapore Paincare’s clinics. [S2, p. 10] [S2, p. 84]

What the audit changed at the parent company

The audit variance notice identifies an additional impairment assessment for investments in subsidiaries. The audited parent company recorded a S$1.76 million impairment charge for FY2026, and its accumulated losses at 30 June stood at S$2.50 million, compared with S$1.99 million in the unaudited figures. The company says these parent-level adjustments do not affect the consolidated accounts because intra-group investments and balances are eliminated there. [S1, p. 1] [S1, p. 2] [S2, p. 99]

That distinction matters for a dividend investor. The group’s cash generation does not itself establish that the listed parent will distribute cash. The parent reported S$2.33 million of dividend income from subsidiaries during FY2026, but also ended the year with accumulated losses and S$467,000 in its own cash and bank balances. These figures describe different parts of the group; none is a promised shareholder payout. [S2, p. 82] [S2, p. 116] [S2, p. 128]

Cash improved, with other claims on it

Audited net operating cash flow rose to S$4.38 million from S$2.34 million. After S$258,000 of plant and equipment purchases, that leaves S$4.12 million before acquisitions, lease payments, financing interest and other financing flows. It is a useful measure of cash generation, not a dividend amount. [S2, p. 87]

The audit recast the TS Medical acquisition from a S$24,000 net cash inflow in the unaudited statements to a S$512,000 net outflow. The audited note reconciles S$578,000 of cash consideration with S$66,000 of cash acquired. During FY2026, the group also paid S$616,000 in dividends to non-controlling interests in subsidiaries. Those payments went to minority owners, not Singapore Paincare shareholders. [S1, p. 2] [S2, p. 88] [S2, p. 103]

Bank borrowings fell to S$2.65 million at 30 June 2026 from S$4.00 million a year earlier, while group cash and bank balances declined to S$4.15 million from S$5.20 million. The cash-flow statement records lease principal repayments of S$2.29 million and lease interest of S$195,000. These commitments help explain why stronger operating cash flow did not translate into a shareholder dividend. [S2, p. 82] [S2, p. 87] [S2, p. 88] [S2, p. 117]

What to watch next

The board expressly cited performance and short- and medium-term funding needs when it declined to recommend a FY2026 dividend; FY2025 also had none. The audited figures show genuine progress in operating cash generation, but still a shareholder loss, parent-company accumulated losses and substantial cash commitments. The next results should show whether operating cash remains strong and whether more of it reaches the listed parent before a shareholder payout becomes plausible. [S3, p. 29] [S3, p. 30] [S2, p. 84] [S2, p. 87] [S2, p. 116]